700 patients110,866 observations180 daysLIVE

Patient P-02208

Synthetic patientMETA-24 · Day 133 · 35–44 · F · baseline S14Open companion preview
Therapy response
Declining
Tolerance
Unstable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S14
  2. Day 72 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 76 GI-04 recommendedGI Support Protocol GI-04
  4. Day 77 Patient declinedNot now

What changed?

Trajectory began diverging from predicted response on Day 72.

Primary contributors, last 14 days
  • Nutritional resilience-8
  • Inflammatory activity+5
  • GI instability-4
  • Toxicity+3

What helped?

  • GI Support Protocol GI-04Day 76
    Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 88% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 69 and rising
  • Inflammatory signalling 60
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 70
    • WearableHRV 22 ms, trending down
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 63
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 30/100
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 45
    • WearableResting HR 73 bpm
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2 · butyrate capacity 30/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
24 ms
Sleep
6.0 h
Steps
5,003
Resting HR
72 bpm
Daily log: GI score 69, nutritional resilience 27, adherence 40.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0261053%S14NP-02no change42
P-0259448%S2045
P-0234047%S14NP-02no change46
P-0251147%S0451
P-0258245%S14ME-01improved45
P-0232044%S14NP-02improved50
P-0251444%S05ME-01improved44
P-0203943%S1438
P-0215743%S14ME-01improved55
P-0257142%S11ME-01improved43
P-0269342%S14ME-01improved41
P-0213241%S14SC-12improved40